To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
NCT00143338
Last updated date
ABOUT THIS STUDY
To examine the lung when people with diabetes take an inhaled form of insulin, compared to
subcutaneous insulin.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Diabetes Mellitus, Type 2
Sex
Females and Males
Age
30-55 years
Inclusion Criteria
Show details
- Type 2 Diabetes Mellitus
- Normal lung function
Exclusion Criteria
Show details
- Smokers
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Diabetes Mellitus, Type 2To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
NCT00143338
- Fresno, California
- San Antonio, Texas
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Diabetes Mellitus, Type 2US Inhaled Insulin Dose Titration Study
NCT00246623
- Birmingham, Alabama
- Los Angeles, California
- New Britain, Connecticut
- Norwalk, Connecticut
- Hollywood, Florida
- Atlanta, Georgia
- Boise, Idaho
- Hayden, Idaho
- Baton Rouge, Louisiana
- Boston, Massachusetts
- Albany, New York
- Syracuse, New York
- Dallas, Texas
- El Paso, Texas
- San Antonio, Texas
- Bennington, Vermont
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Diabetes Mellitus, Type 2US Inhaled Insulin Therapeutic Choice Questionnaire Study
NCT00139763
- Chandler, Arizona
- Mesa, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Tempe, Arizona
- Los Angeles, California
- San Diego, California
- Colorado Springs, Colorado
- Newark, Delaware
- Wilmington, Delaware
- Washington, District of Columbia
- Jacksonville, Florida
- Jacksonville, Florida
- Hayden, Idaho
- Nampa, Idaho
- Gurnee, Illinois
- Elkton, Maryland
- Detroit, Michigan
- Minneapolis, Minnesota
- St. Louis, Missouri
- Omaha, Nebraska
- Margate City, New Jersey
- Santa Fe, New Mexico
- New York, New York
- Morehead City, North Carolina
- Salisbury, North Carolina
- Statesville, North Carolina
- Winston-Salem, North Carolina
- Cincinnati, Ohio
- Portland, Oregon
- Portland, Oregon
- Orangeburg, South Carolina
- Simpsonville, South Carolina
- Arlington, Texas
- Dallas, Texas
- Madisonville, Texas
- San Antonio, Texas
- Bennington, Vermont
- Virginia Beach, Virginia
- Spokane, Washington
- Tacoma, Washington
- Milwaukee, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Diabetes Mellitus, Type 212 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin
NCT00473525
- Birmingham, Alabama
- Gilbert, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Jonesboro, Arkansas
- Little Rock, Arkansas
- Carmichael, California
- Chula Vista, California
- Fair Oaks, California
- Los Angeles, California
- National City, California
- Paramount, California
- Roseville, California
- Sacramento, California
- DeFuniak Springs, Florida
- Destin, Florida
- Jacksonville, Florida
- New Port Richey, Florida
- New Port Richey, Florida
- Palm Harbor, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Conyers, Georgia
- Chicago, Illinois
- Skokie, Illinois
- Skokie, Illinois
- Wheeling, Illinois
- Lexington, Kentucky
- Lexington, Kentucky
- Brockton, Massachusetts
- Worcester, Massachusetts
- Ann Arbor, Michigan
- Canton, Michigan
- Flint, Michigan
- Biloxi, Mississippi
- Picayune, Mississippi
- St. Louis, Missouri
- Omaha, Nebraska
- Las Vegas, Nevada
- Las Vegas, Nevada
- Las Vegas, Nevada
- Trenton, New Jersey
- Cary, North Carolina
- Raleigh, North Carolina
- Raleigh, North Carolina
- Marion, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Carnegie, Pennsylvania
- East Providence, Rhode Island
- Bartlett, Tennessee
- Collierville, Tennessee
- Kingsport, Tennessee
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Irving, Texas
- San Antonio, Texas
- San Antonio, Texas
- Richmond, Virginia
- Virginia Beach, Virginia
- Milwaukee, Wisconsin
- Bogota, Cundinamarca
- Bogota, Cundinamarca
- Floridablanca, Santander
- Berlin,
- Giengen,
- Hamburg,
- Muenchen,
- Roma,
- Santiago de Compostela, La Coruña
- Alcala de Henares, Madrid
- Valencia,
- Valencia,
- Goteborg,
- Malmo,
- Stockholm,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin. | |||
Official Title ICMJE | A Phase 2, Exploratory Study to Examine the Effects of Inhaled Insulin, Compared With Subcutaneously Administered Insulin, on Airway Lining Fluid Composition in Subjects With Type 2 Diabetes Mellitus. | |||
Brief Summary | To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Diabetes Mellitus, Type 2 | |||
Intervention ICMJE | Drug: Inhaled insulin | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 20 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | December 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 30 Years to 55 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00143338 | |||
Other Study ID Numbers ICMJE | A2171053 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Sanofi | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | February 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |